ArticleEMBO molecular medicine2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
173 papers cite itlatest 60 shown
this papertrialcites it